Multifaceted roles of peroxisome proliferatoractivated receptors (PPARs) at the cellular and whole organism levels

Swiss Medical Weekly

Volumn 140, Issue SEPTEMBER, 2010, Pages

  Yessoufou, Akadiri ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Inflammation; Metabolic syndrome; PPARs; Sexual dimorphism; Skin wound healing

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; CHEMOKINE RECEPTOR CCR2; CHORIONIC GONADOTROPIN; CLOFIBRATE; CYTOCHROME P450; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; FATTY ACID; GAMMA INTERFERON; GEMFIBROZIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 6; STEROID; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ADIPOPHILIN; CIGLITAZONE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROGESTERONE; TOLL LIKE RECEPTOR; TROGLITAZONE;

ABORTION; ADIPOCYTE; BONE DENSITY; BONE MASS; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CHOLESTEROL TRANSPORT; CYTOKINE PRODUCTION; EMBRYO DEVELOPMENT; ENCEPHALOMYELITIS; ENERGY METABOLISM; ENTERITIS; ENZYME METABOLISM; EXTRAMEDULLARY HEMATOPOIESIS; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; INFLAMMATION; KERATINOCYTE; LIPID STORAGE; LIPOLYSIS; LIPOPHILICITY; LIVER PROTECTION; LIVER TOXICITY; METABOLIC DISORDER; NEWBORN MORTALITY; OSTEOCLAST; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SKIN INJURY; TH2 CELL; TISSUE INJURY; WOUND HEALING; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CELL LEVEL; CELL PROLIFERATION; DENDRITIC CELL; DRUG TARGETING; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FATTY LIVER; FETUS DEVELOPMENT; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIVER FUNCTION; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYSICAL STRESS; PHYSIOLOGICAL STRESS; PLACENTA DEVELOPMENT; POSTNATAL DEVELOPMENT; PSORIASIS; RHEUMATOID ARTHRITIS; SKELETAL MUSCLE; SUMOYLATION; T LYMPHOCYTE; TH1 CELL; WEIGHT GAIN;

EID: 84856008795     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2010.13071     Document Type: Review

References (85)

1. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1):4-7. Review. (Pubitemid 38032801)
2. Desvergne B, Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-88. (Pubitemid 30650602)
3. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal βoxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-87.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-50.
5. Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97:1-3.
6. Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly. 2002;132(7-8):83-91. (Pubitemid 34492280)
7. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94. (Pubitemid 40040538)
8. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 26(5):244-51.
9. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activator receptors. Pharmacol Rev. 2006;58(4):726-41. (Pubitemid 44833742)
10. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys Acta. 2007;1771(8):915-25. (Pubitemid 47208545)
11. Yu S, Reddy, JK. Transcription coactivators for peroxisome proliferatoractivated receptors. Biochim Biophys Acta. 2007;1771(8):936-51. (Pubitemid 47198542)
12. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev. 2005;19(4):453-61. (Pubitemid 40256277)
13. Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogeninduced toxicity in mice. J Clin Invest. 2009;119(10):3138-48.
14. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 2006;116(3):598-606. (Pubitemid 43326864)
15. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121-4. (Pubitemid 47056470)
16. Bosch FX., Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5-16.
17. Crockett ET, Spielman W, Dowlatshahi S, He J. Sex differences in inflammatory cytokine production in hepatic ischemia-reperfusion. J Inflamm. (Lond.). 2006;3:16.
18. Mittendorfer B. Sexual dimorphism in human lipid metabolism. J Nutr. 2005;135:681-6. (Pubitemid 40464088)
19. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58:737-47. (Pubitemid 32553031)
20. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, et al. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol. 2004;65(5):1148-58. (Pubitemid 38543486)
21. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-22. (Pubitemid 37494207)
22. Stapleton G, Steel M, Richardson M, Mason JO, Rose KA, Morris RG, et al. A novel cytochrome P450 expressed primarily in brain. J Biol Chem. 1995;270(50):29739-45. (Pubitemid 26001640)
23. Martin C, Bean R, Rose K, Habib F, Seckl J. Cyp7b1 catalyses the 7alpha-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem J. 2001;355:509-15. (Pubitemid 32397812)
24. Pettersson H, Holmberg L, Axelson M, Norlin M. CYP7B1-mediated metabolism of dehydroepiandrosterone and 5-alpha-androstane -3beta,17beta-diol--potential role(s) for estrogen signaling. FEBS J. 2008;275:1778-89. (Pubitemid 351463998)
25. Tang W, Eggertsen G, Chiang JY, Norlin M. Estrogen-mediated regulation of CYP7B1: a possible role for controlling DHEA levels in human tissues. J Steroid Biochem Mol Biol. 2006;100:42-51. (Pubitemid 44067452)
26. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007;13(10):1185-92. (Pubitemid 47530633)
27. Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem. 2006;281:16625-31.
28. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis. 2007;2:26.
29. Michalik L, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors and cancers: complex stories. Nature Rev Cancer. 2004;4(1):61-70. (Pubitemid 38082154)
30. Rotman N, Michalik L, Desvergne B, Wahli W. PPARs in fetal and early postnatal development. Adv Develop Biol. 2006;16:33-64. (Pubitemid 44725700)
31. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem. 2000;275:28918-28.
32. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489-98.
33. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci. USA 1999;96:7473-8. (Pubitemid 29299686)
34. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl- CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. 1997;272:28210-7. (Pubitemid 27517759)
35. Sato O, Kuriki C, Fukui Y, Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J Biol Chem. 2002;277:15703-11. (Pubitemid 34967844)
36. Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, et al. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. J Pharmacol Exp Ther. 2009;331(3):796-807.
37. Lemberger T, Saladin R, Vázquez M, Assimacopoulos F, Staels B, Desvergne B, et al. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem. 1996;271(3):1764-9. (Pubitemid 26028664)
38. Rotman N, Wahli W. Fatty acid synthesis and PPARalpha hand in hand. Chem Biol. 2009;16(8):801-2.
39. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009;138(3):476-88.
40. Yessoufou A, Hichami A, Besnard P, Moutairou K, Khan NA. Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: Modulation of T cell differentiation. Endocrinology. 2006;147(9):4410-8. (Pubitemid 44268392)
41. Hashimoto F, Oguchi Y, Morita M, Matsuoka K, Takeda S, Kimura M, et al. PPAR-alpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. Biochem Pharmacol. 2004;68:313-21. (Pubitemid 38757700)
42. Michalik L, Desvergne B, Dreyer C, Gavillet M, Laurini RN, Wahli W. PPAR expression and function during vertebrate development. Int J Dev Biol. 2002;46:105-14. (Pubitemid 34226309)
43. Wang Q, Fujii H, Knipp GT. Expression of PPAR and RXR isoforms in the developing rat and human term placentas. Placenta. 2002;23:661-71. (Pubitemid 37184675)
44. Tontonoz P, Hu E, Graves R, Budavari A, Spiegelman B. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8(10):1224-34.
45. Forman B, Tontonoz P, Chen J, Brun R, Spiegelman B, Evans R. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-12. (Pubitemid 3006324)
46. Patsouris D, Reddy JK, Muller M, Kersten S. Peroxisome proliferatoractivated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147:1508-16. (Pubitemid 43244386)
47. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem. 2003;278:498-505. (Pubitemid 36043602)
48. Wahli W. PPAR gamma: ally and foe in bone metabolism. Cell Metab. 2008;7(3):188-90. (Pubitemid 351285532)
49. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846-55. (Pubitemid 38544143)
50. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, et al. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep. 2004;5:1007-12. (Pubitemid 39534460)
51. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β/δ. Mol Cell Biol. 2006;26:3266-81.
52. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-95. (Pubitemid 29531138)
53. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-7. (Pubitemid 43326863)
54. Lim H, Dey SK. PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab. 2000;11:137-42. (Pubitemid 30238546)
55. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol. 2000;20:5119-28. (Pubitemid 30431565)
56. Mano H, Kimura C, Fujisawa Y, Kameda T, Watanabe-Mano M, Kaneko H, et al. Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts. J Biol Chem. 2000;275:8126-32. (Pubitemid 30159727)
57. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K. Peroxisome proliferator-activated receptor-δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem. 2001;276:3175-82.
58. Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4(5):407-14. (Pubitemid 44645068)
59. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci. USA 2001;98:5306-11. (Pubitemid 32397124)
60. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidaemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivatordependent receptor ligand assay. Mol Endocrinol. 1997;11:779-91. (Pubitemid 27225305)
61. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001;142:4195-202. (Pubitemid 32907045)
62. Hoekstra M, Kruijt JK, Van Eck M, Van Berkel TJ. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem. 2003;278:25448-53. (Pubitemid 36835295)
63. Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, et al. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology. 2008;47:225-35. (Pubitemid 351171060)
64. Sanderson LM, Boekschoten MV, Desvergne B, Müller M, Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol Genomics. 2010;41(1):42-52.
65. Ravnskjaer K, Frigerio F, Boergesen M, Nielsen T, Maechler P, Mandrup S. PPARδ is a fatty acid sensor, which enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid induced dysfunction. J Lipid Res. 2009 Nov 30. [Epub ahead of print] PMID: 19965574.
66. Coll T, Rodrïguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, et al. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr Mol Pharmacol. 2009;2(1):46-55.
67. Kielian T, Drew PD. Effects of perixosome proliferator activated receptor-g agonists on central nervous system inflammation. J Neurosci Res. 2003;71:315-25. (Pubitemid 36159491)
68. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol. 2004;172:5790-8. (Pubitemid 38542085)
69. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341-9. (Pubitemid 44277368)
70. Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM, et al. Protective effects of a peroxisome proliferator activated receptor- b/d agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;168:65-75. (Pubitemid 41396404)
71. Attakpa E, Hichami A, Simonin AM, Sansón EG, Dramane KL, Khan NA. Docosahexaenoic acid modulates the expression of T-bet and GATA-3 transcription factors, independently of PPARalpha, through suppression of MAP kinase activation. Biochimie. 2009;91(11-12):1359-65.
72. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 1999;274:32048-54.
73. Takano H, Hasegawa H, Nagai T, Komuro I. The role of PPARγ dependent pathway in the development of cardiac hypertrophy. Drugs Today. (Barc) 2003;39:347-57. (Pubitemid 36890282)
74. Shah YM, Morimura K, Gonzalez FJ. Expression of peroxisome proliferator activated receptor-g in macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G657-66.
75. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, et al. Peroxisome proliferator activated receptor gamma in colonic epi- thelial cells protects against experimental inflammatory bowel disease. Gut. 2006;55:1104-11.
76. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551-8. (Pubitemid 350101420)
77. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:323-30. (Pubitemid 40823539)
78. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyper-lipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998;36:345-9. (Pubitemid 28271555)
79. Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008;2008:1-15.
80. Michalik L, B. Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J Cell Biol. 2001;154:799-814.
81. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 2001;15:3263-77. (Pubitemid 34008192)
82. Michalik L, Feige JN, Gelman L, Pedrazzini T, Keller H, Desvergne B, et al. Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. Mol Endocrinol. 2005;19:2335-48. (Pubitemid 41252826)
83. Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, et al. Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/ delta is essential for skin homeostasis and wound healing. J Cell Biol. 2009;184(6):817-31.
84. Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, et al. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier, J Clin Invest. 1997;100:705-12. (Pubitemid 27340520)
85. Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol. 2004;123:305-12. (Pubitemid 38951825)